share_log

Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494

Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494

Stifel維持對福泰製藥的持有評級,將目標價格提高至494美元
Benzinga ·  2024/12/16 21:17  · 評級/大行評級

Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $490 to $494.

Stifel分析師保羅·馬泰斯維持Vertex Pharmicals(納斯達克股票代碼:VRTX)的持倉並將目標股價從490美元上調至494美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論